379 related articles for article (PubMed ID: 19542207)
1. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes.
Larsen CM; Faulenbach M; Vaag A; Ehses JA; Donath MY; Mandrup-Poulsen T
Diabetes Care; 2009 Sep; 32(9):1663-8. PubMed ID: 19542207
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-1-receptor antagonist in type 2 diabetes mellitus.
Larsen CM; Faulenbach M; Vaag A; Vølund A; Ehses JA; Seifert B; Mandrup-Poulsen T; Donath MY
N Engl J Med; 2007 Apr; 356(15):1517-26. PubMed ID: 17429083
[TBL] [Abstract][Full Text] [Related]
3. The interleukin-1 receptor antagonist anakinra improves first-phase insulin secretion and insulinogenic index in subjects with impaired glucose tolerance.
van Poppel PC; van Asseldonk EJ; Holst JJ; Vilsbøll T; Netea MG; Tack CJ
Diabetes Obes Metab; 2014 Dec; 16(12):1269-73. PubMed ID: 25039318
[TBL] [Abstract][Full Text] [Related]
4. IL-1 receptor antagonism and muscle gene expression in patients with type 2 diabetes.
Berchtold LA; Larsen CM; Vaag A; Faulenbach M; Workman CT; Kruhøffer M; Donath M; Mandrup-Poulsen T
Eur Cytokine Netw; 2009 Jun; 20(2):81-7. PubMed ID: 19541594
[TBL] [Abstract][Full Text] [Related]
5. The antiinflammatory cytokine interleukin-1 receptor antagonist protects from high-fat diet-induced hyperglycemia.
Sauter NS; Schulthess FT; Galasso R; Castellani LW; Maedler K
Endocrinology; 2008 May; 149(5):2208-18. PubMed ID: 18239070
[TBL] [Abstract][Full Text] [Related]
6. Amyloid formation disrupts the balance between interleukin-1β and interleukin-1 receptor antagonist in human islets.
Hui Q; Asadi A; Park YJ; Kieffer TJ; Ao Z; Warnock GL; Marzban L
Mol Metab; 2017 Aug; 6(8):833-844. PubMed ID: 28752047
[TBL] [Abstract][Full Text] [Related]
7. Anakinra treatment in patients with refractory inflammatory myopathies and possible predictive response biomarkers: a mechanistic study with 12 months follow-up.
Zong M; Dorph C; Dastmalchi M; Alexanderson H; Pieper J; Amoudruz P; Barbasso Helmers S; Nennesmo I; Malmström V; Lundberg IE
Ann Rheum Dis; 2014 May; 73(5):913-20. PubMed ID: 23625983
[TBL] [Abstract][Full Text] [Related]
8. Administration of IL-1ra improves adiponectin levels in chronic hemodialysis patients.
Hung AM; Limkunakul C; Placido JS; Siew ED; Ellis CD; Shintani A; Ikizler TA
J Nephrol; 2014 Dec; 27(6):681-8. PubMed ID: 24609887
[TBL] [Abstract][Full Text] [Related]
9. Treatment with Anakinra improves disposition index but not insulin sensitivity in nondiabetic subjects with the metabolic syndrome: a randomized, double-blind, placebo-controlled study.
van Asseldonk EJ; Stienstra R; Koenen TB; Joosten LA; Netea MG; Tack CJ
J Clin Endocrinol Metab; 2011 Jul; 96(7):2119-26. PubMed ID: 21508140
[TBL] [Abstract][Full Text] [Related]
10. β Cell-Specific Deletion of the IL-1 Receptor Antagonist Impairs β Cell Proliferation and Insulin Secretion.
Böni-Schnetzler M; Häuselmann SP; Dalmas E; Meier DT; Thienel C; Traub S; Schulze F; Steiger L; Dror E; Martin P; Herrera PL; Gabay C; Donath MY
Cell Rep; 2018 Feb; 22(7):1774-1786. PubMed ID: 29444430
[TBL] [Abstract][Full Text] [Related]
11. Exenatide Increases IL-1RA Concentration and Induces Nrf-2‒Keap-1‒Regulated Antioxidant Enzymes: Relevance to β-Cell Function.
Dandona P; Ghanim H; Abuaysheh S; Green K; Dhindsa S; Makdissi A; Batra M; Kuhadiya ND; Chaudhuri A
J Clin Endocrinol Metab; 2018 Mar; 103(3):1180-1187. PubMed ID: 29346597
[TBL] [Abstract][Full Text] [Related]
12. The safety and efficacy of interleukin-1 receptor antagonist in the treatment of rheumatoid arthritis.
Bresnihan B
Semin Arthritis Rheum; 2001 Apr; 30(5 Suppl 2):17-20. PubMed ID: 11357167
[TBL] [Abstract][Full Text] [Related]
13. Preliminary studies related to anti-interleukin-1β therapy in children with newly diagnosed type 1 diabetes.
Sumpter KM; Adhikari S; Grishman EK; White PC
Pediatr Diabetes; 2011 Nov; 12(7):656-67. PubMed ID: 21518168
[TBL] [Abstract][Full Text] [Related]
14. Association of soluble apoptotic markers with impaired left ventricular deformation in patients with rheumatoid arthritis. Effects of inhibition of interleukin-1 activity by anakinra.
Ikonomidis I; Tzortzis S; Lekakis J; Paraskevaidis I; Dasou P; Parissis J; Nikolaou M; Markantonis SL; Katsimbri P; Skarantavos G; Andreadou I; Anastasiou-Nana M
Thromb Haemost; 2011 Nov; 106(5):959-67. PubMed ID: 21947196
[TBL] [Abstract][Full Text] [Related]
15. Muscle-Derived IL-6 Is Not Regulated by IL-1 during Exercise. A Double Blind, Placebo-Controlled, Randomized Crossover Study.
Nordmann TM; Seelig E; Timper K; Cordes M; Coslovsky M; Hanssen H; Schmidt-Trucksäss A; Donath MY
PLoS One; 2015; 10(10):e0139662. PubMed ID: 26448147
[TBL] [Abstract][Full Text] [Related]
16. SCIL-STROKE (Subcutaneous Interleukin-1 Receptor Antagonist in Ischemic Stroke): A Randomized Controlled Phase 2 Trial.
Smith CJ; Hulme S; Vail A; Heal C; Parry-Jones AR; Scarth S; Hopkins K; Hoadley M; Allan SM; Rothwell NJ; Hopkins SJ; Tyrrell PJ
Stroke; 2018 May; 49(5):1210-1216. PubMed ID: 29567761
[TBL] [Abstract][Full Text] [Related]
17. Effects of intraarticular IL1-Ra for acute anterior cruciate ligament knee injury: a randomized controlled pilot trial (NCT00332254).
Kraus VB; Birmingham J; Stabler TV; Feng S; Taylor DC; Moorman CT; Garrett WE; Toth AP
Osteoarthritis Cartilage; 2012 Apr; 20(4):271-8. PubMed ID: 22273632
[TBL] [Abstract][Full Text] [Related]
18. The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis.
Kalliolias GD; Liossis SN
Expert Opin Investig Drugs; 2008 Mar; 17(3):349-59. PubMed ID: 18321234
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study.
Vastert SJ; de Jager W; Noordman BJ; Holzinger D; Kuis W; Prakken BJ; Wulffraat NM
Arthritis Rheumatol; 2014 Apr; 66(4):1034-43. PubMed ID: 24757154
[TBL] [Abstract][Full Text] [Related]
20. Accelerated increase in serum interleukin-1 receptor antagonist starts 6 years before diagnosis of type 2 diabetes: Whitehall II prospective cohort study.
Carstensen M; Herder C; Kivimäki M; Jokela M; Roden M; Shipley MJ; Witte DR; Brunner EJ; Tabák AG
Diabetes; 2010 May; 59(5):1222-7. PubMed ID: 20185814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
